vs

Side-by-side financial comparison of DBV Technologies S.A. (DBVT) and PureCycle Technologies, Inc. (PCT). Click either name above to swap in a different company.

DBV Technologies S.A. is the larger business by last-quarter revenue ($2.8M vs $2.7M, roughly 1.0× PureCycle Technologies, Inc.). PureCycle Technologies, Inc. runs the higher net margin — -697.1% vs -1195.5%, a 498.4% gap on every dollar of revenue. DBV Technologies S.A. produced more free cash flow last quarter ($-32.6M vs $-42.0M).

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.

DBVT vs PCT — Head-to-Head

Bigger by revenue
DBVT
DBVT
1.0× larger
DBVT
$2.8M
$2.7M
PCT
Higher net margin
PCT
PCT
498.4% more per $
PCT
-697.1%
-1195.5%
DBVT
More free cash flow
DBVT
DBVT
$9.5M more FCF
DBVT
$-32.6M
$-42.0M
PCT

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
DBVT
DBVT
PCT
PCT
Revenue
$2.8M
$2.7M
Net Profit
$-33.2M
$-18.8M
Gross Margin
Operating Margin
-1235.7%
-2196.1%
Net Margin
-1195.5%
-697.1%
Revenue YoY
158.8%
Net Profit YoY
-8.9%
71.0%
EPS (diluted)
$-0.24
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DBVT
DBVT
PCT
PCT
Q4 25
$2.7M
Q3 25
$2.8M
$2.4M
Q2 25
$1.5M
$1.6M
Q1 25
$1.6M
Q4 24
$0
Q3 24
$0
Q2 24
$1.2M
$0
Q1 24
$1.4M
$0
Net Profit
DBVT
DBVT
PCT
PCT
Q4 25
$-18.8M
Q3 25
$-33.2M
$-28.4M
Q2 25
$-41.9M
$-144.2M
Q1 25
$8.8M
Q4 24
$-64.7M
Q3 24
$-90.6M
Q2 24
$-33.1M
$-48.2M
Q1 24
$-27.3M
$-85.6M
Operating Margin
DBVT
DBVT
PCT
PCT
Q4 25
-2196.1%
Q3 25
-1235.7%
-1602.2%
Q2 25
-2806.2%
-2763.5%
Q1 25
-2387.4%
Q4 24
Q3 24
Q2 24
-2914.9%
Q1 24
-2029.7%
Net Margin
DBVT
DBVT
PCT
PCT
Q4 25
-697.1%
Q3 25
-1195.5%
-1167.5%
Q2 25
-2858.4%
-8741.8%
Q1 25
559.0%
Q4 24
Q3 24
Q2 24
-2852.4%
Q1 24
-1943.5%
EPS (diluted)
DBVT
DBVT
PCT
PCT
Q4 25
$-0.14
Q3 25
$-0.24
$-0.31
Q2 25
$-0.31
$-0.81
Q1 25
$0.05
Q4 24
$-0.40
Q3 24
$-0.54
Q2 24
$-0.34
$-0.29
Q1 24
$-0.28
$-0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DBVT
DBVT
PCT
PCT
Cash + ST InvestmentsLiquidity on hand
$69.8M
$156.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$52.9M
$45.9M
Total Assets
$110.5M
$922.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DBVT
DBVT
PCT
PCT
Q4 25
$156.7M
Q3 25
$69.8M
$234.4M
Q2 25
$103.2M
$284.1M
Q1 25
$22.5M
Q4 24
$15.7M
Q3 24
$83.7M
Q2 24
$66.2M
$10.9M
Q1 24
$101.5M
$25.0M
Stockholders' Equity
DBVT
DBVT
PCT
PCT
Q4 25
$45.9M
Q3 25
$52.9M
$68.2M
Q2 25
$86.2M
$98.9M
Q1 25
$238.2M
Q4 24
$180.4M
Q3 24
$241.4M
Q2 24
$79.1M
$291.6M
Q1 24
$111.7M
$336.8M
Total Assets
DBVT
DBVT
PCT
PCT
Q4 25
$922.7M
Q3 25
$110.5M
$989.1M
Q2 25
$143.4M
$1.0B
Q1 25
$787.3M
Q4 24
$798.4M
Q3 24
$788.8M
Q2 24
$114.2M
$719.8M
Q1 24
$145.9M
$734.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DBVT
DBVT
PCT
PCT
Operating Cash FlowLast quarter
$-32.4M
$-28.7M
Free Cash FlowOCF − Capex
$-32.6M
$-42.0M
FCF MarginFCF / Revenue
-1173.5%
-1559.6%
Capex IntensityCapex / Revenue
4.2%
495.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-138.3M
$-183.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DBVT
DBVT
PCT
PCT
Q4 25
$-28.7M
Q3 25
$-32.4M
$-38.5M
Q2 25
$-33.9M
$-36.7M
Q1 25
$-38.9M
Q4 24
$-31.8M
Q3 24
$-33.4M
Q2 24
$-35.1M
$-40.4M
Q1 24
$-34.7M
$-39.2M
Free Cash Flow
DBVT
DBVT
PCT
PCT
Q4 25
$-42.0M
Q3 25
$-32.6M
$-42.4M
Q2 25
$-33.9M
$-45.3M
Q1 25
$-53.9M
Q4 24
$-53.4M
Q3 24
$-42.6M
Q2 24
$-35.8M
$-50.8M
Q1 24
$-36.0M
$-53.5M
FCF Margin
DBVT
DBVT
PCT
PCT
Q4 25
-1559.6%
Q3 25
-1173.5%
-1743.1%
Q2 25
-2316.5%
-2747.1%
Q1 25
-3409.6%
Q4 24
Q3 24
Q2 24
-3084.0%
Q1 24
-2560.6%
Capex Intensity
DBVT
DBVT
PCT
PCT
Q4 25
495.1%
Q3 25
4.2%
160.3%
Q2 25
2.2%
521.5%
Q1 25
949.6%
Q4 24
Q3 24
Q2 24
63.0%
Q1 24
94.9%
Cash Conversion
DBVT
DBVT
PCT
PCT
Q4 25
Q3 25
Q2 25
Q1 25
-4.40×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons